Cargando…
A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer
Olaparib was first FDA approved for use in women with advanced ovarian cancer and germline BRCA mutations. Based on the results of subsequent research, the use of this drug has been expanded to patients with metastatic breast cancer with germline BRCA mutation. With the use of a relatively new medic...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040243/ https://www.ncbi.nlm.nih.gov/pubmed/30050710 http://dx.doi.org/10.1155/2018/9529821 |